Edge Therapeutics Announces Pricing of its Initial Public Offering
Berkeley Heights, NJ – September 30, 2015 – Edge Therapeutics, Inc. today announced the pricing of its
initial public offering of 7,315,151 shares of its common stock at a public offering price of $11.00 per share,
before underwriting discounts and commissions. All of the shares of common stock are being offered by Edge
Therapeutics. In addition, Edge Therapeutics granted the underwriters a 30-day option to purchase up to an
additional 1,097,272 shares of common stock at the same price, to cover over-allotments, if any. The shares
are scheduled to begin trading on The NASDAQ Global Select Market on October 1, 2015 under the ticker
Leerink Partners and Credit Suisse are acting as joint book-running managers for the offering. Guggenheim
Securities and JMP Securities are acting as co-managers.
The offering is being made only by means of a prospectus. A copy of the final prospectus related to this
offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from
Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or
by email at firstname.lastname@example.org, or by phone at (800) 808-7525, ext. 6124, or Credit Suisse Securities
(USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by telephone at
(800) 221-1037, or by email at email@example.com.
A registration statement relating to the securities being sold in this offering was declared effective by the
Securities and Exchange Commission on September 30, 2015. This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under
the securities laws of any such state or jurisdiction.
About Edge Therapeutics
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to
commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the
management of acute, life-threatening neurological conditions. EG-1962, our lead product candidate, has the
potential to fundamentally improve patient outcomes and transform the management of aneurysmal
subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm.
EG-1964, our second product candidate, is being evaluated as a potential prophylactic treatment in the
management of chronic subdural hematoma, to prevent recurrent bleeding on the surface of the brain. For
additional information about Edge Therapeutics, please visit www.edgetherapeutics.com.
Edge Therapeutics, Inc.
Tel: 1-800-208-EDGE (3343)